So, further we expect that Low-dose lymphocyte immunotherapy might be an effective therapy for prostate cancer, and even NDUFA13, UQCR11, and USP34 might be immunocheckpoints like PD-1/ PD-L1, they may play its role through Th2 and Tcm cells. The gene discussed is USP34; the disease is prostate carcinoma.